Solid Waste Landfill Performance During the 1994 Northridge Earthquake

The performance of 22landfills in the Los Angeles area during the January 17, 1994 Northridge earthquake has been investigated. Observations of damage at these landfills indicate that the overall performance of solid waste landfills was encouraging. None of the surveyed landfills showed any signs of major damage. However, one geosynthetic-lined landfill experienced two tears in the geomembrane liner. Most landfills within 30 km of the zone of energy release experienced some form of cracking in the soil cover. Beyond approximately 40 km from the zone of energy release, little to no damage was observed

Incorporating social practices in BDI agent systems

When agents interact with humans, either through embodied agents or because they are embedded in a robot, it would be easy if they could use fixed interaction protocols as they do with other agents. However, people do not keep fixed protocols in their day-to-day interactions and the environments are often dynamic, making it impossible to use fixed protocols. Deliberating about interactions from fundamentals is not very scalable either, because in that case all possible reactions of a user have to be considered in the plans. In this paper we argue that social practices can be used as an inspiration for designing flexible and scalable interaction mechanisms that are also robust. However, using social practices requires extending the traditional BDI deliberation cycle to monitor landmark states and perform expected actions by leveraging existing plans. We define and implement this mechanism in Jason using a periodically run meta-deliberation plan, supported by a metainterpreter, and illustrate its use in a realistic scenario.Comment: An extended abstract of this paper has been accepted for the Eighteenth International Conference on Autonomous Agents and Multiagent Systems (AAMAS), 201

Conveying Audience Emotions through Humanoid Robot Gestures to an Orchestra during a Live Musical Exhibition

In the last twenty years, robotics have been applied in many heterogeneous contexts. Among them, the use of humanoid robots during musical concerts have been proposed and investigated by many authors. In this paper, we propose a contribution in the area of robotics application in music, consisting of a system for conveying audience emotions during a live musical exhibition, by means of a humanoid robot. In particular, we provide all spectators with a mobile app, by means of which they can select a specific color while listening to a piece of music (act). Each color is mapped to an emotion, and the audience preferences are then processed in order to select the next act to be played. This decision, based on the overall emotion felt by the audience, is then communicated by the robot through body gestures to the orchestra. Our first results show that spectators enjoy such kind of interactive musical performance, and are encouraging for further investigations

Oleocanthal Exerts Antitumor Effects on Human Liver and Colon Cancer Cells Through ROS Generation

The beneficial health properties of the Mediterranean diet are well recognized. The principle source of fat in Mediterranean diet is extra-virgin olive oil (EVOO). Oleocanthal (OC) is a naturally occurring minor phenolic compound isolated from EVOO, which has shown a potent anti-inflammatory activity, by means of its ability to inhibit the cyclooxygenase (COX) enzymes COX-1 and COX-2. A large body of evidence indicates that phenols exhibit anticancer activities. The aim of the present study was to evaluate the potential anticancer effects of OC in hepatocellular carcinoma (HCC) and colorectal carcinoma (CRC) models. A panel of human HCC (HepG2, Huh7, Hep3B and PLC/PRF/5) and CRC (HT29, SW480) cell lines was used. Cells were treated with OC, and cell viability and apoptosis were evaluated. Compared with classical commercially available COX inhibitors (ibuprofen, indomethacin, nimesulide), OC was more effective in inducing cell growth inhibition in HCC and CRC cells. Moreover, OC inhibited colony for mation and i nduced ap optosis, as confirmed by PARP cleavage, activation of caspases 3/7 and chromatin condensation. OC treatment in a dose dependent-manner induced expression of \uce\ub3H2AX, a marker of DNA damage, increased intracellular ROS production and caused mitochondrial depolarization. Moreover, the effects of OC were suppressed by the ROS scavenger N-acetyl-L-cysteine. Finally, OC was not toxic in primary normal human hepatocytes. In conclusion, OC treatment was found to exert a potent anticancer activity against HCC and CRC cells. Taken together, our findings provide preclinical support of the chemotherapeutic potential of EVOO against cancer

The masses of the neutron and donor star in the high mass X-ray binary IGR J18027-2016

We report near-infrared observations of the supergiant donor to the eclipsing high mass X-ray binary pulsar IGR J18027-2016. We aim to determine its spectral type and measure its radial velocity curve and hence determine the stellar masses of the components. ESO/VLT observations of the donor utilising the NIR spectrograph ISAAC were obtained in the H and K bands. The multi-epoch H band spectra were cross-correlated with RV templates in order to determine a radial solution for the system. The spectral type of the donor was confirmed as B0-1 I. The radial velocity curve constructed has a semi-amplitude of $23.8 \pm 3.1$ km s$^{-1}$. Combined with other measured system parameters, a dynamically determined neutron star mass of 1.4 $\pm$ 0.2 - 1.6 $\pm$ 0.3 M$_{\odot}$ is found. The mass range of the B0-B1 I donor was 18.6 $\pm$ 0.8 - 21.8 $\pm$ 2.4 ~M$_{\odot}$. These lower and upper limits were obtained under the assumption that the system is viewed edge-on (i = 90$^\circ$ with $\beta$ = 0.89) for the lower limit and the donor fills its Roche lobe ($\beta = 1$ with i = 73.1$^\circ$) for the upper limit respectively.Comment: 5 pages, 4 figures, Accepted for publication in A&

Consequence of the tumor-associated conversion to cyclin D1b.

Clinical evidence suggests that cyclin D1b, a variant of cyclin D1, is associated with tumor progression and poor outcome. However, the underlying molecular basis was unknown. Here, novel models were created to generate a genetic switch from cyclin D1 to cyclin D1b. Extensive analyses uncovered overlapping but non-redundant functions of cyclin D1b compared to cyclin D1 on developmental phenotypes, and illustrated the importance of the transcriptional regulatory functions of cyclin D1b in vivo. Data obtained identify cyclin D1b as an oncogene, wherein cyclin D1b expression under the endogenous promoter induced cellular transformation and further cooperated with known oncogenes to promote tumor growth in vivo. Further molecular interrogation uncovered unexpected links between cyclin D1b and the DNA damage/PARP1 regulatory networks, which could be exploited to suppress cyclin D1b-driven tumors. Collectively, these data are the first to define the consequence of cyclin D1b expression on normal cellular function, present evidence for cyclin D1b as an oncogene, and provide pre-clinical evidence of effective methods to thwart growth of cells dependent upon this oncogenic variant

Congenic Mesenchymal Stem Cell Therapy Reverses Hyperglycemia in Experimental Type 1 Diabetes

OBJECTIVE - A number of clinical trials are underway to test whether mesenchymal stem cells (MSCs) are effective in treating various diseases, including type 1 diabetes. Although this cell therapy holds great promise, the optimal source of MSCs has yet to be determined with respect to major histocompatibility complex matching. Here, we examine this question by testing the ability of congenic MSCs, obtained from the NOR mouse strain, to reverse recent-onset type 1 diabetes in NOD mice, as well as determine the immunomodulatory effects of NOR MSCs in vivo. RESEARCH DESIGN AND METHODS - NOR MSCs were evaluated with regard to their in vitro immunomodulatory function in the context of autoreactive T-cell proliferation and dendritic cell (DC) generation. The in vivo effect of NOR MSC therapy on reversal of recent-onset hyperglycemia and on immunogenic cell subsets in NOD mice was also examined. RESULTS - NOR MSCs were shown to suppress diabetogenic T-cell proliferation via PD-L1 and to suppress generation of myeloid/inflammatory DCs predominantly through an IL-6-dependent mechanism. NOR MSC treatment of experimental type 1 diabetes resulted in long-term reversal of hyperglycemia, and therapy was shown to alter diabetogenic cytokine profile, to diminish T-cell effector frequency in the pancreatic lymph nodes, to alter antigen-presenting cell frequencies, and to augment the frequency of the plasmacytoid subset of DCs. CONCLUSIONS - These studies demonstrate the inimitable benefit of congenic MSC therapy in reversing experimental type 1 diabetes. These data should benefit future clinical trials using MSCs as treatment for type 1 diabetes

The 1 - 50 keV spectral and timing analysis of IGR J18027-2016: an eclipsing, high mass X-ray binary

We report the association of the INTEGRAL source IGR J18027-2016 with the BeppoSAX source SAX J1802.7-2017. IGR J18027-2016 is seen to be a weak, persistent source by the IBIS/ISGRI instrument on board INTEGRAL with an average source count rate of 0.55 counts s^-1 (~6.1 mCrab) in the 20-40 keV band. Timing analysis performed on the ISGRI data identifies an orbital period of 4.5696 +/- 0.0009 days and gives an ephemeris of mid-eclipse as, T{mid} = 52931.37 +/- 0.04 MJD. Re-analysis of archival BeppoSAX data has provided a mass function for the donor star, f(m) = 16 +/- 1 M{sun} and a projected semimajor axis of a{x}sin{i} = 68 +/- 1 lt-s. We conclude that the donor is an OB-supergiant with a mass of 18.8-29.3 M{sun} and a radius of 15.0-23.4 R{sun}. Spectra obtained by XMM-Newton and ISGRI indicate a high hydrogen column density of NH = 6.8 x 10^22 cm^-2, which suggests intrinsic absorption. The source appears to be a high mass X-ray binary with the neutron star emitting X-rays through wind-fed accretion while in an eclipsing orbit around an OB-supergiant.Comment: Accepted for Publication in A&A. 9 pages, 10 figures. Figure 10 has been compressed, lowering the image qualit

MICL controls inflammation in rheumatoid arthritis

Acknowledgments We thank G Milne, D MacCallum, S Hardison, G Wilson, C Wallace, S Hadebe and A Richmond for assistance; H. El-Gabalawy for tissues and the animal facility staff for the care of our animals. Flow cytometry was undertaken in the Iain Fraser Cytometry Centre, University of Aberdeen. Funding: GDB was funded by the Wellcome Trust and MRC (UK). AA and CDB are supported by the Arthritis Research UK Tissue Engineering Centre (grant 19429). This study makes use of data generated by the Wellcome Trust Case Control Consortium. A full list of the investigators who contributed to the generation of the data is available from http://www.wtccc.org.uk, and was funded by the Wellcome Trust (076113). MJGF was funded by The Arthritis Society and the Canadian Arthritis Network and J-ML by a scholarship from the Canadian Arthritis Network.Peer reviewedPublisher PD